Evidence map›Paper›PMID 27274912›Full record

ReviewBioResearch open access2016

Microbiota and Neurological Disorders: A Gut Feeling.

Walter H Moos, Douglas V Faller, David N Harpp, Iphigenia Kanara, Julie Pernokas, Whitney R Powers, Kosta Steliou

Erratum issuedOpen access · diamondAbstract readReview
In one paragraph

Review in BioResearch open access, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 147 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Antioxidants (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    2017
5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Walter H MoosDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco , San Francisco, California.
Douglas V FallerDepartment of Medicine, Boston University School of Medicine, Boston, Massachusetts.; Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts.
David N HarppDepartment of Chemistry, McGill University , Montreal, Canada .
Iphigenia KanaraWeatherhead Center for International Affairs, Harvard University, Cambridge, Massachusetts.; Consulate General of Greece in Boston, Boston, Massachusetts.
Julie PernokasAdvanced Dental Associates of New England, Woburn, Massachusetts.
Whitney R PowersDepartment of Health Sciences, Boston University, Boston, Massachusetts.; Department of Anatomy, Boston University School of Medicine, Boston, Massachusetts.
Kosta SteliouCancer Research Center, Boston University School of Medicine, Boston, Massachusetts.; PhenoMatriX, Inc., Boston, Massachusetts.
Boston University · USAdvanced Pharma · USEmulate (United States) · USMcGill University · CAUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host-microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota-host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.

Indexed as

autismdementiadysbiosisepigeneticexercisefatty acidshistone deacetylaseimmune systemmicrobiotamitochondrianeurodegenerativeprobioticsschizophreniasynthetic biologyα-lipoic acid

Identifiers

PMID27274912
PMCPMC4892191
OpenAlexW2402588103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.